Previous Article | Next Article ![]()
Journal of Virology, December 2001, p. 11886-11890, Vol. 75, No. 23
Department of
Microbiology1 and Center for Clinical
Epidemiology and Biostatistics,2 Cancer
Center, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania 19104-6142
Received 20 April 2001/Accepted 28 August 2001
The mouse mammary tumor virus (MMTV) superantigen induces T-cell
production of cytokines, such as interleukin-4, which in turn increase
MMTV transcription. However, interleukin-4 is not required for in vivo
virus spread, because mice lacking interleukin-4 or the STAT6
transcription factor showed wild-type infection of lymphoid and mammary
tissue. In spite of this, mammary tumor incidence was decreased in
STAT6 null mice.
Virus infection in vivo leads to
many interactions with cells of the immune system. In the case of mouse
mammary tumor virus (MMTV), which is acquired neonatally through
milk-borne transmission, the infection pathway directly involves
lymphocytes. Initially, MMTV activates and infects B cells in the
Peyer's patches of the small intestine, probably through interaction
between the envelope (Env) protein and one or more molecules on the
surfaces of these cells (2). One such molecule that
interacts with the MMTV Env is Toll-like receptor 4 (TLR4), and this
binding activates NF- Subsequent to their initial activation, B cells become infected and
present a viral superantigen (Sag) protein to cognate T cells.
Presentation of viral Sag to cognate T cells results in their
activation and the production of cytokines that stimulate these B cells
(1, 35). At least in adult mice, B cells that receive this
Sag-mediated T cell help differentiate into immunoglobulin G2a
(IgG2a)-secreting plasma cells several days after injection of virus
(11, 20, 22). Both B and T cells become infected in this
process (8), and either cell type can transmit virus to
uninfected wild-type (42) or SCID (36) mice.
T-cell help is provided to B cells through cell-cell interactions
(CD40/CD40L; B7/CD28), many of which have been shown to be important
for efficient MMTV infection in vivo (4, 5, 31). In adult
mice that receive MMTV through a subcutaneous route, there is an
initial production of predominantly type 1 cytokines, including gamma
interferon and IL-2. There is B-cell production of IgG2a (21,
31), although it is not known whether milk-borne infection also
induces IgG2a production. Later in the infection process, IL-4 is made
(40), indicating that MMTV also results in the
differentiation of T-helper 2 (Th2) cells, the subset that induces
B-cell differentiation in response to cytokines such as IL-4 and IL-13
(6, 25, 28). Interaction of either of these cytokines with
its receptor activates the signal transducer and activator of
transcription factor 6 (STAT6) (33), and mice that have
deletions in either the IL-4 or STAT6 genes have a paucity of Th2 cells
(17, 38). Many cytokine and hormone receptors induce
transcription through different Janus kinase (JAK)/STAT pathways
(13, 37). In addition to the IL-4 receptor and STAT6, for
example, activation of the receptors for prolactin and IL-2 results in
signaling through the STAT5 transcription factors. There are two genes
that encode STAT5, 5a and 5b, with distinct but overlapping functions
in vivo (23, 39). We have shown previously that there is a
STAT-like element in the long terminal repeat (LTR) of this virus that
binds to STAT5 transcription factors and that prolactin induces virus
transcription in mammary tissue culture cells (32). The
IL-1 receptor, in contrast, belongs to the TLR/IL-1 receptor family,
which signals through NF- As MMTV is expressed both in T and B cells (8), and
because virus infection results in cytokine production through the action of the Env and Sag proteins, we determined whether cytokines such as IL-1, IL-2, and IL-4 induce proviral transcription in lymphocytes. We first tested whether any of these cytokines induced transcription from endogenous MMTV loci in cultured primary
splenocytes. Splenocytes were isolated from BALB/c mice and cultured in
medium alone or in the presence of IL-1 (0.02 µg/ml; R&D Systems,
Minneapolis, Minn.), IL-2 (50 U/ml), LPS (5 µg/ml), concanavalin A
(ConA; 2 µg/ml; Sigma, St. Louis, Mo.) (Fig.
1), or IL-4 (100 U/ml; Gibco/BRL, Rockville, Md.) (Fig. 2) for 48 h
(Fig. 1) or 20 h (Fig. 2). Total RNA was isolated using
Trizol reagent (Gibco/BRL), and 40 µg was subjected to RNase
protection using probes specific for the Mtv-9 and Mtv-6 proviruses, as
previously described (9). Five micrograms of RNA from each
sample was also subjected to Northern blot analysis and hybridized with
a probe for mouse
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11886-11890.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Interleukin-4 Up-Regulates Mouse Mammary Tumor
Virus Expression yet Is Not Required for In Vivo Virus Spread


![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
B transcription factors, followed by the
production of cytokines such as interleukin-1 (IL-1) and IL-6 (J. C. Rassa, J. L. Meyers, Y. Zhang, R. Kudaravalli, and S. R. Ross, submitted for publication).
B transcription factors as well as other
pathways (29). It has been shown that activation of TLR4
with bacterial lipopolysaccharide (LPS) induces MMTV transcription
(3, 18). There is no consensus NF-
B site in the MMTV
LTR, although a functional site in the env gene has been
identified (I. Nepomnaschy and I. Piazzon, personal communication).
-actin (Fig. 1A). We found that IL-1, -2, and -4 all induced transcription of both the Mtv-6 and -9 proviruses in
primary splenocytes cultured with these cytokines (Fig. 1 and 2).
Similarly, LPS and ConA, a T-cell activator which has been shown to
signal through multiple pathways, also induced transcription of Mtv-6
and -9. In contrast, IL-6, also induced by activation of TLR4, had no
effect on endogenous MMTV transcription (data not shown).

View larger version (42K):
[in a new window]
FIG. 1.
Cytokine induction of endogenous MMTV transcripts. (A)
RNase protection of RNA from BALB/c splenocytes cultured in medium
alone (
) or with IL-2, LPS, or ConA. (B) RNase protection of RNA from
BALB/c splenocytes cultured as for panel A in the presence of IL-2,
IL-1, or LPS. + cont, positive control mammary gland RNA.

View larger version (55K):
[in a new window]
FIG. 2.
IL-4 induction of MMTV RNA in BALB/c,
IL-4
/
(top), and STAT6
/
(bottom) mice.
Although the RNA sample for untreated IL-4
/
splenocytes
(
) was slightly degraded, there is clear induction of Mtv-9 by IL-4
treatment (compare IL-2 and IL-4 treatment). C, BALB/c RNA control for
the
-actin reaction.
We next tested whether splenocytes isolated from transgenic mice
bearing the MMTV LTR linked to the bacterial chloramphenicol acetyltransferase (CAT) gene showed increased enzymatic activity in the
presence of either IL-2 or IL-4 (32). Splenocytes from transgenic LTR1-CAT mice were cultured with medium alone or in the
presence of IL-2 (300 U/ml) or IL-4 (100 U/ml) (Gibco/BRL) for 48 h. Extracts were prepared, and CAT assays were performed as previously
described (32). The CAT activity in LTR1 mice was
stimulated on average 3.5-fold by IL-2, while induction by IL-4 was
6.5-fold (Fig. 3). The relative induction
by IL-2 and IL-4 was similar to that seen with the endogenous
proviruses (Fig. 1 and 2) and showed that induction of transcription
maps to the LTR.
|
Since IL-2 and IL-4 both induced MMTV transcription, we tested whether
mice that lacked STAT5a, IL-4, or STAT6 were susceptible to MMTV
infection. IL-4 and STAT6 knockout mice as well as the BALB/cJ controls
were obtained from The Jackson Laboratory; the STAT5a mice, initially
obtained from L. Hennighausen (19), were bred at the
University of Pennsylvania. First we examined whether the initial
activation of B cells by virus was altered after subcutaneous injection
of MMTV(LA). Virus was isolated from mammary tumor tissue of
MMTV(LA)-infected mice and footpad injections were performed, as
previously described (8). At 20 and 96 h following
MMTV(LA) injection into the right footpad, lymphocytes were harvested
from the draining lymph node and from the contralateral nondraining lymph node as a control. Lymphocytes were stained with fluorescein isothiocyanate-conjugated anti-B220, anti-V
6 [for MMTV(LA) Sag cognate T cells], and anti-V
10 (for noncognate T cells)
antibodies and phycoerythrin-conjugated anti-CD69 or anti-CD4
antibodies (Pharmingen, San Diego, Calif.). As expected, the ability of
MMTV to induce B-cell activation, as measured by expression of CD69, was not affected by the mutations, since this is the result of direct
virus-B-cell interaction (Table 1)
(2; Rassa et al., submitted). The difference between the
STAT5a
/
and other mice in this assay probably
reflects the influence of strain background (mixed C57BL/6 and
129 crossed to C3H/HeN for two generations for the
STAT5a
/
mice versus BALB/c for the
IL-4
/
and STAT6
/
mice).
|
We next determined whether Sag presentation in the knockout mice
occurred by measuring the response of both T and B lymphocytes at
96 h after subcutaneous injection of MMTV. No significant
differences were seen in any of animals in the Sag-mediated
V
6-bearing T-cell activation or the T-cell-mediated B-cell
stimulation (Table 1).
After the initial Sag stimulation of cognate T cells, there is a
gradual deletion of these cells in MMTV-infected mice
(12). The kinetics of deletion can reflect the level of
virus infection, since mice that are not highly infected delete their
cognate T cells more slowly than those that are highly infected
(10). We therefore examined Sag-mediated deletion of
V
6-bearing T cells. BALB/c, IL-4
/
, and
STAT6
/
mice were foster nursed on C3H/HeN
MMTV(LA)+ mothers and bled at the indicated times
(Fig. 4). Peripheral blood lymphocytes
were stained with fluorescein isothiocyanate-conjugated anti-V
6 and
phycoerythrin-conjugated anti-CD4 antibodies (Pharmingen). We found
that Sag-mediated deletion occurred with similar kinetics in
MMTV(LA)-infected BALB/c, IL-4
/
, and
STAT6
/
mice (Fig. 4). Although not
statistically significant, deletion appeared to occur somewhat earlier
in the mutant mice but reached the same ultimate level. We also found
that STAT5a
/
mice infected with MMTV(C3H)
showed deletion kinetics of the Sag-cognate V
14 T-cell population
similar to those of C3H/HeN mice (not shown). Thus, the lack of
cytokine-mediated stimulation in the null mice did not affect
MMTV-mediated activation of B or T cells, nor did it affect virus
infection of lymphocytes.
|
We then used RNase protection analysis of viral RNA in milk to examine
infection of mammary tissue in all three strains of mice. RNA was
isolated from the milk of MMTV(LA)-infected mice at the second
pregnancy, and 10 µg was subjected to an RNase protection assay using
probes specific to MMTV(LA) and mouse
-actin. Not surprisingly,
STAT5a null mice showed no defects in infection by MMTV (data not
shown). It has been reported that STAT5a null mice have defects in
their T-cell compartment (16, 26) and show some
alterations in their mammary gland biology (19). However, in most cases the STAT5b protein has been shown to compensate for these
defects (39). Additionally, although the
-actin levels were variable in milk RNA, we found that both the IL-4 and STAT6 knockout mice had wild-type infection of their mammary tissue (Fig.
5). Thus, although the cytokines produced
by the Sag-activated T cells stimulate MMTV transcription, loss of any
single cytokine response was not sufficient to decrease mammary gland
infection.
|
STAT6
/
mice lack a major signaling pathway
for the type 2 cytokines IL-4 and IL-13 and show defects in the
expression of a number of genes that are regulated by these cytokines,
such as major histocompatibility complex, Thy-1, and CD23
(38). However other pathways for these cytokines exist,
such as phosphorylation of the insulin receptor substrate followed by
activation of phosphatidylinositol 3-kinase (14). To
determine whether other pathways operated in the IL-4-mediated
induction of MMTV transcription in the STAT6
/
mice, we performed RNase protection assays using probes specific for
the Mtv-6 and -9 loci on RNA isolated from splenocytes cultured in
medium alone or in the presence of IL-2 (50 U/ml), IL-4 (100 U/ml;
Gibco/BRL), and LPS (5 µg/ml; Sigma) for 20 h. As a control, these experiments were also performed with the
IL-4
/
mice that retain IL-4 receptors and are
thus fully responsive to this cytokine. The
STAT6
/
mice showed normal induction of Mtv-9
(Fig. 2) and Mtv-6 (data not shown) transcription. Thus, IL-4 must
initiate signaling through other pathways in the null mice that result
in MMTV transcription. Other functions of IL-4 have been shown to be
independent of STAT6 in null mice, including the death of resting T
cells, the ability to control Friend virus infection, and the induction
of IgE production and murine AIDS by the LP-BM5 murine leukemia virus
(7, 24, 41).
The STAT6
/
and
IL-4
/
mice were generated in the BALB/c
background, a strain that does not normally generate good Th1 cellular immune responses to pathogens such as Leishmania
(34). In adult mice, infection by MMTV has been shown to
predominantly generate a Th1 immune response, characterized by the
production of IgG2a (21), although whether this occurs
neonatally during natural milk-borne infection is not known. When the
STAT6 mutation is introduced into the BALB/c background, in the
absence of a Th2 response the default becomes a stronger Th1 response,
with increased levels of IgG2a and other type 1 antibodies (17,
38). Thus, both the IL-4 and STAT6 null mice, both of which also
have increased cellular immunity due to this profound shift to the Th1
type of T cell, might be expected to have decreased infection of
mammary tissue if a stronger Th1 response eliminated virus-infected
cells more effectively. If, however, there was a strong antiviral
response that required Th2 cells, these mice should have shown higher
levels of infection. Since there was no apparent change in the virus load in the null mice, the change in the balance of Th1 and Th2 cells
apparently did not affect antiviral immune responses.
Interestingly, the one difference between the wild-type BALB/c and
STAT6 knockout mice was that the mutant mice had an increased latency
of mammary tumorigenesis. BALB/c, STAT6
/
, and
IL-4
/
mice were foster nursed on C3H/HeN
MMTV(LA)+ mothers and monitored for tumor
development. Both the mean and median times to tumor development were
significantly longer for MMTV-infected STAT6
/
mice (mean of 287.5 days; median of 271 days) than for BALB/c mice
(mean of 232.3 days; median of 215 days) (Fig.
6). IL-4
/
mice
also showed a delay in tumor development (mean of 263.1 days; median of
255 days), although the difference was not statistically significant
compared to BALB/c mice.
|
It has been observed previously that BALB/c mice, which have poor Th1
responses, are more susceptible to MMTV(C3H)-induced mammary tumors
than are C3H/HeN mice, which have normal Th1 responses (average mean
latency of tumor incidence of about 7 months versus 9 months for the
two strains) (8, 27). The increased susceptibility in
BALB/c mice is not the result of increased lymphocyte infection; it was
shown previously that the lymphoid tissues of BALB/c mice have lower
virus levels than C3H/HeN mice (8). Moreover, there seems
to be no correlation between tumor latency and the infection levels in
mammary tissue, as shown here, since there was no difference in the
virus load in STAT6
/
and BALB/c mice (Fig.
5). One possible explanation for the increased latency in
STAT6
/
mice is increased immune recognition
of tumor cells in these mice. Recent work from other labs has shown
that antitumor immunity is increased in STAT6 null mice, resulting in
the decreased growth of transplanted tumor cells (15, 30).
The natural lack of a good Th1 antitumor response in the wild-type
BALB/c background may therefore contribute to the increased
susceptibility of these inbred mice to MMTV-induced mammary tumors
compared to strains like C3H/HeN.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jackie Dudley and members of her laboratory for thoughtful comments on the manuscript and Isabel Piazzon and Irene Nepomnaschy for helpful discussions.
This work was supported by PHS R01-CA45954. J. Czarneski was supported by NRSA F32 CA83344.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: 313BRB2, 421 Curie Blvd., Philadelphia, PA 19104. Phone: (215) 898-9764. Fax: (215) 573-2028. E-mail: rosss{at}mail.med.upenn.edu.
Present address: Whitehead Institute, Cambridge, MA 02142.
Present address: Department of Environmental Medicine, University
of Pennsylvania School of Medicine, Philadelphia, PA 19104.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Acha-Orbea, A., D. Finke, A. Attinger, S. Schmid, N. Wehrli, S. Vacheron, L. Xenarios, L. Scarpellino, K.-M. Toellner, I. C. M. MacLennan, and S. A. Luther. 1999. Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Immunol. Rev. 168:287-303[CrossRef][Medline]. |
| 2. | Ardavin, C., F. Luthi, M. Andersson, L. Scarpellino, P. Martin, H. Diggelmann, and H. Acha-Orbea. 1997. Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J. Virol. 71:7295-7299[Abstract]. |
| 3. | Carr, J. K., V. L. Traina-Dorge, and J. C. Cohen. 1985. Mouse mammary tumor virus gene expression regulated in trans by Lps locus. Virology 147:210-213[CrossRef][Medline]. |
| 4. | Champagne, E., L. Scarpellino, P. Lane, and H. Acha-Orbea. 1996. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Eur. J. Immunol. 26:1595-1602[Medline]. |
| 5. | Chervonsky, A. V., J. Xu, A. K. Barlow, M. Khery, R. A. Flavell, and C. A. Janeway, Jr. 1995. Direct physical interaction involving CD40 ligand on T cells and CD40 on B cells is required to propagate MMTV. Immunity 3:139-146[CrossRef][Medline]. |
| 6. | Constant, S. L., and K. Bottomly. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297-322[CrossRef][Medline]. |
| 7. |
Dittmer, U.,
K. Peterson,
R. Messer,
I. M. Stromnes,
B. Race, and K. J. Hasenkrug.
2001.
Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.
J. Virol.
75:654-660 |
| 8. | Dzuris, J. L., T. V. Golovkina, and S. R. Ross. 1997. Both T and B cells shed infectious MMTV. J. Virol. 71:6044-6048[Abstract]. |
| 9. |
Golovkina, T. V.,
A. B. Jaffe, and S. R. Ross.
1994.
Coexpression of exogenous and endogenous mouse mammary tumor virus RNA in vivo results in viral recombination and broadens the virus host range.
J. Virol.
68:5019-5026 |
| 10. |
Golovkina, T. V.,
J. A. Prescott, and S. R. Ross.
1993.
Mouse mammary tumor virus-induced tumorigenesis in sag transgenic mice: a laboratory model of natural selection.
J. Virol.
67:7690-7694 |
| 11. |
Held, W.,
A. N. Shaknow,
S. Izui,
G. A. Waanders,
L. Scarpellino,
H. R. MacDonald, and H. Acha-Orbea.
1993.
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.
J. Exp. Med.
177:359-366 |
| 12. |
Ignatowicz, L.,
J. Kappler, and P. Marrack.
1992.
The effects of chronic infection with a superantigen-producing virus.
J. Exp. Med.
175:917-923 |
| 13. | Ihle, J. N., and I. M. Kerr. 1995. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11:69-74[CrossRef][Medline]. |
| 14. |
Johnson, J. A.,
L.-M. Wang,
E. P. Hanson,
X.-J. Sun,
M. F. White,
S. A. Oakes,
J. H. Pierce, and J. J. O'Shea.
1995.
Interleukins 1, 4, 7 and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells.
J. Biol. Chem.
270:28527-28530 |
| 15. | Kacha, A., F. Fallarino, M. A. Markiewicz, and T. F. Gajewski. 2000. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6124-6128. |
| 16. |
Kagami, S.,
H. Nakajima,
K. Kumano,
K. Suzuki,
A. Suto,
K. Imada,
H. W. Davey,
Y. Saito,
K. Takatsu,
W. J. Leonard, and I. Iwamoto.
2000.
Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue.
Blood
95:1370-1377 |
| 17. | Kaplan, M. H., U. Schindler, S. T. Smiley, and M. J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity 4:313-319[CrossRef][Medline]. |
| 18. |
King, L. B., and R. B. Corley.
1990.
Lipopolysaccharide and dexamethasone induce mouse mammary tumor proviral gene expression and differentiation in B lymphocytes through distinct regulatory pathways.
Mol. Cell. Biol.
10:4211-4220 |
| 19. |
Liu, X.,
G. W. Robinson,
K. U. Wagner,
L. Garrett,
A. Wynshaw-Boris, and L. Hennighausen.
1997.
Stat5a is mandatory for adult mammary gland development and lactogenesis.
Genes Dev.
11:179-186 |
| 20. |
Luther, S. A.,
A. Gulbranson-Judge,
H. Acha-Orbea, and I. C. M. MacLennan.
1996.
Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production.
J. Exp. Med.
185:551-562 |
| 21. | Luther, S. A., I. Maillard, F. Luthi, L. Scarpellino, H. Diggelmann, and H. Acha-Orbea. 1997. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. J. Immunol. 159:2807-2814[Abstract]. |
| 22. |
Maillard, I.,
P. Launois,
I. Xenarios,
J. A. Louis,
H. Acha-Orbea, and H. Diggelmann.
1998.
Immune response to mouse mammary tumor virus in mice lacking the alpha/beta interferon or the gamma interferon receptor.
J. Virol.
72:2638-2646 |
| 23. | Morrigl, R., D. J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, A. van Deursen, M. Y. Sangster, K. D. Bunting, G. C. Grosveld, and J. N. Ihle. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10:249-259[CrossRef][Medline]. |
| 24. |
Morse, H. C., III,
T. McCarty,
N. A. Giese,
L. Taddesse-Heath, and M. J. Grusby.
1999.
STAT6-deficient mice exhibit normal induction of murine AIDS and expression of immunoglobulin E following infection with LP-BM5 murine leukemia viruses.
J. Virol.
73:7093-7095 |
| 25. | Murphy, K. 1998. T lymphocyte differentiation in the periphery. Curr. Opin. Immunol. 10:226[CrossRef][Medline]. |
| 26. |
Nakajima, H.,
X. W. Liu,
A. Wynshaw-Boris,
L. A. Rosenthal,
K. Imada,
D. S. Finbloom,
L. Hennighausen, and W. J. Leonard.
1997.
An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor chain induction.
Immunity
7:691-701[CrossRef][Medline].
|
| 27. | Nandi, S., and C. M. McGrath. 1973. Mammary neoplasia in mice. Adv. Cancer Res. 17:353-414[CrossRef]. |
| 28. | O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275[CrossRef][Medline]. |
| 29. | O'Neill, L. A. J. 8 August 2000, posting date. The interleukin-1 receptor/toll-like receptor superfamily: signal transduction during inflammation and host defense, p. 1-11. Sci. Strike [Online.] http://www.stke.org/cgi/content/full/oc_sigtrans;2000/44/re1. |
| 30. |
Ostrand-Rosenberg, S.,
M. J. Grusby, and V. K. Clements.
2000.
STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
J. Immunol.
165:6015-6019 |
| 31. | Palmer, L. D., B. Saha, R. J. Hodes, and R. Abe. 1996. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses. J. Immunol. 156:2112-2118[Abstract]. |
| 32. |
Qin, W.,
T. V. Golovkina,
T. Peng,
I. Nepomnaschy,
V. Buggiano,
I. Piazzon, and S. R. Ross.
1999.
Mammary gland expression of mouse mammary tumor virus is regulated by a novel element in the long terminal repeat.
J. Virol.
73:368-376 |
| 33. | Quelle, F. W., K. Shimoda, W. Thierfelder, C. Fischer, A. Kim, S. M. Ruben, J. L. Cleveland, J. H. Pierce, A. D. Keegan, K. Nelms, W. E. Paul, and J. N. Ihle. 1995. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol. Cell. Biol. 15:3336-3343[Abstract]. |
| 34. | Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177[CrossRef][Medline]. |
| 35. | Ross, S. R. 2000. Using genetics to probe host-virus interactions: the mouse mammary tumor virus model. Microbes Infect. 2:1215-1223[CrossRef][Medline]. |
| 36. | Ross, S. R., J. L. Dzuris, T. V. Golovkina, W. C. Clemmons, and B. van den Hoogen. 1997. Mouse mammary tumor virus (MMTV), a retrovirus that exploits the immune system. Medicina (Buenos Aires) 57:34-42. |
| 37. | Schindler, C., and J. E. Darnell, Jr. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64:621-651[Medline]. |
| 38. | Shimoda, K., J. van Deursen, M. Y. Sangster, Sr. Sarawar, R. T. Carson, R. A. Tripp, C. Chu, F. W. Quelle, T. Nosaka, D. A. A. Vignali, P. C. Doherty, G. Grosveld, W. E. Paul, and J. N. Ihle. 1996. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630-633[CrossRef][Medline]. |
| 39. | Teglund, S., C. McKay, E. Schuetz, J. M. van Deursen, D. Stravopodis, D. W. M. Brown, S. Bodner, G. Grosveld, and J. N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, role in cytokine responses. Cell 93:841-850[CrossRef][Medline]. |
| 40. | Toellner, K.-M., S. A. Luther, D. M. Y. Sze, R. K. W. Choy, D. R. Taylor, I. C. M. MacLennan, and H. Acha-Orbea. 1998. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J. Exp. Med. 8:1193-1204. |
| 41. |
Vella, A.,
T. K. Teague,
J. Ihle,
J. Kappler, and P. Marrack.
1997.
Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: Stat6 is probably not required for the effect of IL-4.
J. Exp. Med.
186:325-330 |
| 42. |
Waanders, G. A.,
A. N. Shakhov,
W. Held,
P. Karapetian,
H. Acha-Orbea, and H. R. MacDonald.
1993.
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus.
J. Exp. Med.
177:1359-1366 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»